These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23545592)

  • 1. Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes.
    Ando Y; Shimada H; Matsumoto N; Hirota T; Oribe M; Otsuka E; Ishii K; Morimoto T; Ohashi K; Ieiri I
    Drug Metab Pharmacokinet; 2013; 28(5):442-5. PubMed ID: 23545592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
    Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
    Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.
    Dervieux T; Kremer J; Lein DO; Capps R; Barham R; Meyer G; Smith K; Caldwell J; Furst DE
    Pharmacogenetics; 2004 Nov; 14(11):733-9. PubMed ID: 15564880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis.
    den Boer E; de Rotte MC; Pluijm SM; Heil SG; Hazes JM; de Jonge R
    J Rheumatol; 2014 Nov; 41(11):2167-78. PubMed ID: 25225283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
    Dervieux T; Furst D; Lein DO; Capps R; Smith K; Caldwell J; Kremer J
    Ann Rheum Dis; 2005 Aug; 64(8):1180-5. PubMed ID: 15677700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate.
    Stamp LK; Chapman PT; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Kennedy MA; Roberts RL
    Pharmacogenet Genomics; 2010 Jun; 20(6):367-76. PubMed ID: 20386493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis.
    Murosaki T; Nagatani K; Sato T; Akiyama Y; Ushijima K; Lefor AK; Fujimura A; Minota S
    Mod Rheumatol; 2017 May; 27(3):411-416. PubMed ID: 27435295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis.
    Yamamoto T; Shikano K; Nanki T; Kawai S
    Sci Rep; 2016 Oct; 6():35615. PubMed ID: 27752107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
    Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
    Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients.
    Sandhu A; Ahmad S; Kaur J; Bhatnagar A; Dhawan V; Dhir V
    Clin Rheumatol; 2018 Dec; 37(12):3221-3228. PubMed ID: 30022368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.
    Kung TN; Dennis J; Ma Y; Xie G; Bykerk V; Pope J; Thorne C; Keystone E; Siminovitch KA; Gagnon F
    Arthritis Rheumatol; 2014 May; 66(5):1111-20. PubMed ID: 24782176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.
    Pan S; Stamp LK; Duffull SB; Barclay ML; Dalrymple JM; Drake J; Zhang M; Korell J
    Clin Pharmacokinet; 2014 Dec; 53(12):1161-70. PubMed ID: 25204405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.
    Hobl EL; Jilma B; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Rizovski B; Mader RM
    Clin Exp Rheumatol; 2012; 30(2):156-63. PubMed ID: 22152098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?
    Danila MI; Hughes LB; Brown EE; Morgan SL; Baggott JE; Arnett DK; Bridges SL
    Curr Rheumatol Rep; 2010 Oct; 12(5):342-7. PubMed ID: 20665136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells.
    Korell J; Stamp LK; Barclay ML; Dalrymple JM; Drake J; Zhang M; Duffull SB
    Clin Pharmacokinet; 2013 Jun; 52(6):475-85. PubMed ID: 23483363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
    Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
    Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
    Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
    Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
    Samara SA; Irshaid YM; Mustafa KN
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Dervieux T; Orentas Lein D; Marcelletti J; Pischel K; Smith K; Walsh M; Richerson R
    Clin Chem; 2003 Oct; 49(10):1632-41. PubMed ID: 14500588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.